CONNECT WITH US
HealthTech

HealthTech

Republicans contend with lack of drug policy action, despite controlling Congress

Healthcare Dive logo

Published on

Add as a preferred source on Google
Republicans contend with lack of drug policy action, despite controlling Congress

Drug costs are too high, lawmakers agreed at a Senate committee hearing this week. But industry pushback and delays have stalled reform of a system experts say is rigged.

Congress isn’t quite done pointing a finger at drugmakers and pharmacy benefit managers for their roles in the prescription drug affordability crisis. But members of the Senate Judiciary Committee acknowledged on Tuesday the three fingers aimed back at them.

“I am embarrassed that my side has been in control for two years, and we've done nothing. Zero, zilch, nada,” Sen. John Kennedy, R-La., said during the hearing.

Although the Senate committee advanced six bipartisan bills last year aimed at lowering drug costs, only one bill – the Affordable Prescriptions for Patients Act, which would limit how many brand-name biologic patents a drugmaker can use to sue companies making lower-cost biosimilars – made it to the Senate floor.

Judiciary Chairman Chuck Grassley, R-Iowa, said it wasn’t clear why the bills have stalled, although a crowded legislative calendar and strong industry pushback likely contributed.

The lack of reform from the Republican-led Congress comes despite President Donald Trump’s interest in lowering drug prices. Trump launched his own platform earlier this year for people to buy drugs directly from manufacturers at discounted rates similar to Mark Cuban’s Cost Drug Plus Company.

Still, lawmakers at the hearing said addressing exorbitant drug costs remains a bipartisan issue, with both sides of the aisle calling explicitly for legislative action on PBM reform and the stalled bills.

Passing the six bills cleared by the committee last year – which tackle patient and regulatory loopholes that have allowed PBMs and drugmakers to maximize profits, as well as PBM self-dealing and vertical integration – should be a priority, industry experts said at the hearing.


Source link

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.